Company Overview of Noven Pharmaceuticals, Inc.
Noven Pharmaceuticals, Inc. engages in the research, development, manufacture, marketing, and sale of prescription pharmaceutical products in the United States. The company’s products focus on women’s health, as well as central nervous system disorders, including attention deficit hyperactivity disorder (ADHD). Its products include Brisdelle, a non-hormonal therapy for vasomotor symptoms associated with menopause; Minivelle, an estrogen therapy patch for the treatment of vasomotor symptoms due to menopause and prevention of post-menopausal osteoporosis; CombiPatch, an estradiol/norethindrone acetate transdermal system to treat symptoms of hot flashes, and vaginal dryness associated with meno...
11960 SW 144th Street
Miami, FL 33186
Founded in 1987
Key Executives for Noven Pharmaceuticals, Inc.
Chief Financial Officer, Vice President and Treasurer
Vice President of Operations
Chief Medical Officer and Executive Vice President of Product Development
Vice President, General Counsel and Corporate Secretary
Compensation as of Fiscal Year 2016.
Noven Pharmaceuticals, Inc. Key Developments
Noven Pharmaceuticals, Inc. Reaches Agreement with Sebela International Limited to Assign Rights of Approval for Manufacture, Commercialization and Associated Intellectual Property for Brisdelle Capsules and Pexeva Tablets
Jul 26 16
Hisamitsu Pharmaceutical Co., Inc. announced that its wholly owned subsidiary in the United States, Noven Pharmaceuticals, Inc. has reached agreement with Sebela International Limited to assign rights of approval for manufacture, commercialization and associated intellectual property for Brisdelle (Paroxetine) Capsules, 7.5 mg and Pexeva (Paroxetine Mesylate) Tablets to Sebela.
Noven Pharmaceuticals, Inc. Announces Executive Changes
Mar 7 16
Noven Pharmaceuticals, Inc. announced the appointment of Dolores Calicchio as the company's new Vice President of Human Resources, succeeding Lance Williams, who will be retiring in April. In this role, Calicchio will lead and be responsible for all human resources activities impacting Noven's workforce across the U.S. Prior to joining Noven, Calicchio served as the Vice President of Human Resources at Carnival Cruise Lines. As Noven's Vice President of Human Resources, Calicchio will report directly to Noven's Chief Executive Officer, Jeff Mihm. Regarding Calicchio's appointment.
Noven Pharmaceuticals, Inc. Announces Management Changes
Jan 5 16
Noven Pharmaceuticals, Inc. announced that Jeff Mihm has been appointed as Noven’s Chief Executive Officer, succeeding Jeffrey Eisenberg. Mr. Mihm joined Noven in 2003 and since then has been consistently promoted to senior leadership positions of increasing scope and importance. Most recently, he served as Vice President, Chief Administrative Officer & General Counsel, where he oversaw Noven’s Business Development, Corporate Affairs, Human Resources, Information Technology and Legal/Compliance functions. Prior to Noven, he served as Senior Corporate Counsel to Panamerican Beverages, Inc., and previously was a partner with the law firm of Steel Hector & Davis (now part of Squire Patton Boggs). John Choi has been appointed as Vice President, Chief Financial Officer & Treasurer, succeeding Michael Price. Mr. Choi has served Noven since 2010, most recently as Noven’s Executive Director – Business Planning & Analysis. Prior to Noven, Mr. Choi served as Director of Commercial Operations & Planning for Ther-Rx (a branded pharmaceutical division of KV Pharmaceuticals). Michael Greene has been appointed as Vice President, General Counsel & Corporate Secretary, succeeding Jeff Mihm in those roles. Mr. Greene has served Noven since 2010, most recently as Noven’s Deputy General Counsel & Executive Director – Alliance Management. Prior to Noven, Mr. Greene was an attorney at the law firm of Paul, Hastings, Janofsky & Walker, where he specialized in mergers and acquisitions (M&A) and other complex corporate transactions, including pharmaceutical industry transactions.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|